GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (OTCPK:AVCTF) » Definitions » 3-Year EBITDA Growth Rate

Avacta Group (Avacta Group) 3-Year EBITDA Growth Rate

: -7.00% (As of Jun. 2023)
View and export this data going back to 2015. Start your Free Trial

Avacta Group's EBITDA per Share for the six months ended in Jun. 2023 was $-0.02.

During the past 3 years, the average EBITDA Per Share Growth Rate was -7.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -11.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avacta Group was 60.80% per year. The lowest was -286.20% per year. And the median was -3.70% per year.


Competitive Comparison

For the Biotechnology subindustry, Avacta Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group 3-Year EBITDA Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Avacta Group's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Avacta Group's 3-Year EBITDA Growth Rate falls into.



Avacta Group 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Avacta Group  (OTCPK:AVCTF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Avacta Group 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Avacta Group's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group (Avacta Group) Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (Avacta Group) Headlines

From GuruFocus

LG Chem Renews License Triggering Payment to Avacta

By Business Wire Business Wire 06-30-2022

Avacta and Mologic Announce Commercial Partnership

By Business Wire Business Wire 02-08-2021

Avacta Launches SARS-CoV-2 BAMS Research Test

By Business Wire Business Wire 09-30-2020

Avacta Appoints Dr Christina Coughlin as Non-Executive Director

By Business Wire Business Wire 03-21-2022

Avacta Selects Second pre|CISION� Pro-drug Candidate for Development

By Business Wire Business Wire 01-18-2022

Avacta Submits Clinical Trial Application for AVA6000 pro-doxorubixin

By Business Wire Business Wire 12-23-2020

Avacta Appoints COVID-19 Rapid Antigen Test Manufacturing Partner

By Business Wire Business Wire 08-06-2020